NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Contact the NSABP   Pathology Section   Future Meetings   NSABP Newsletters   Media Info on cMYC Study   Media Info on STAR   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-36   Protocol B-37   Protocol B-39   Protocol B-40   Protocol B-41   Protocol B-42   Protocol C-10   Protocol R-04 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR   BreastCancerPrevention.com Bibliography of Publications Related Web Sites About the NSABP Web Site Helper Applications Links to Major Search Engines Medical Search Engines To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview Protocol B-33 A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating The Effect Of Exemestane In Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing At Least Five Years Of Tamoxifen Therapy Specific Aims The primary aim of this randomized, placebo-controlled, double-blind clinical trial is to determine whether oral administration of exenestane, for 2 years, in postmenopausal patients with estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PgR+) breast cancer (cT1-3 cN0-1 M0) who have completed 5 years of tamoxifen therapy, will prolong disease-free survival when compared with placebo. Secondary aims of this study are to determine whether administration of 2 years of exemestane following 5 years of tamoxifen therapy is more effective than giving 5 years of tamoxifen alone in prolonging overall survival and time to treatment failure.